ASCO Annual Meeting

Data from the RAMPART trial showed that durvalumab monotherapy missed the DFS threshold in resected RCC, though the combination with tremelimumab showed significant benefit.

Andrew J. Armstrong, MD, MSc, discusses efficacy results from a phase 2 study evaluating a chemoimmunotherapy regimen for patients with neuroendocrine or aggressive-variant metastatic prostate cancer.

Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

The primary end point—12-month DFS rate—was 80% (40/50 evaluable patients; 95% CI, 0.67-0.89), with 2 patients pending assessment and 3 not evaluable.

Praful Ravi, MB, BChir, MRCP, discusses results from PSMAtrack, which assessed changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer.

Pedro C. Barata, MD, MSc, FACP, discusses preliminary findings from the phase 3 ProstACT Global study evaluating 177Lu-rosopatamab plus standard of care for patients with mCRPC.

PSA50 response rates were 58.8% overall in Group A (72.7% at 10 MBq), 85.2% overall in Group B (100% at 10 MBq), and 52.5% overall in Group C (56.3% at 10 MBq).

Tanya B. Dorff, MD, FASCO, shares phase 1 data on ABBV-969, an investigational antibody-drug conjugate being explored for metastatic castration-resistant prostate cancer.

"Together with the efficacy and safety results, these PRO findings support the overall benefit-risk profile of perioperative EV plus [pembrolizumab] as the new standard of care in this patient population," said Peter H. O'Donnell, MD.

Kim Chi, MD, highlights findings from a pre-planned analysis of the PLUDO trial examining the impact of crossover on survival outcomes between 177Lu-PSMA-617 vs docetaxel in mCRPC.

"Compared to placebo [plus] ADT, apalutamide [plus] ADT showed 9 times more pCR/MRD, a 20% improved MFS, a 29% reduction in prostate cancer recurrence, and a 3-year improvement in time to subsequent therapy," said Mary-Ellen Taplin, MD, FASCO.

Lucia Nappi, MD, PhD, FRCPC, highlights key findings from an interim analysis of SWOG S1823, evaluating miR371 for predicting active germ cell malignancy in patients with early-stage testicular cancer.

Study investigator Gopa Iyer, MD, concluded that LY4052031 represents a promising next-generation Nectin-4 ADC with a distinct payload mechanism that may overcome EV resistance in mUC.

"These data help inform patient decision-making regarding adjuvant therapy and also point to a possible need for supportive services to help survivors after treatment," said Ronald C. Chen, MD, MPH, FASCO, FASTRO.

Alicia K. Morgans, MD, MPH, discusses key findings from the ARACOG study, assessing cognitive outcomes between patients who received darolutamide vs those who received enzalutamide for advanced prostate cancer.

The phase 2 ARACOG trial noted a greater decline in objectively measured cognitive function over 24 weeks among patients who received enzalutamide vs darolutamide for advanced prostate cancer.

"There is some evidence here, supported by our statistical analysis plan, that the classifier predicted the postulated benefits of adding docetaxel to ADT and enzalutamide," said Christopher Sweeney, MBBS, DHS.

Rana R. McKay, MD, FASCO, highlights phase 2 data on radium-223 dichloride plus cabozantinib for patients with renal cell carcinoma with bone metastases.

At a median follow-up of 42.8 months, median OS was 33.6 months (95% CI, 26.6–39.8) with EV+P (240 events/442 patients) vs 15.9 months (95% CI, 13.6–18.3) with chemotherapy (329 events/444 patients).

"Twenty-seven of 40 patients achieved a pCR amounting to a rate of 68%. Therefore, the null hypothesis could be rejected," said Richard Cathomas, MD.

Mark Fleming, MD, and Manoj Bupathi, MD, MS, highlight the key studies and sessions in GU oncology that they're most anticipating at ASCO 2026.

Christof Vulsteke, MD, PhD, shares in-depth insights on the 3.5-year analysis of the EV-302 trial, evaluating enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Data also showed that ctDNA positivity at baseline was associated with worse DFS outcomes.

Although the primary end point was not met, Rana R. McKay, MD, highlighted a notable divergence in OS curves after 1 year that she described as a signal warranting further investigation.

Jad Chahoud, MD, MPH, MHA, discusses the mechanism of action for zanzalintinib and walks through key design elements of the STELLAR-002 trial.

The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.

EV+P demonstrated superior efficacy to chemotherapy across all specified subgroups assessed.

Data showed that Non-Hispanic Black and Latinx/Hispanic patients were less likely to receive PSMA-PET imaging than non-Hispanic White patients.

According to the authors, the mitomycin/BCG regimen could alleviate some of the burden of the global BCG shortage.